News & Updates

Use of opioid among adults with knee and/or hip osteoarthritis (OA) often leads to being familiar with the treatment and believing that the medication is beneficial and low-risk, reveals a recent study.

In individuals with clinically diagnosed mild-to-moderate Alzheimer’s disease (AD), treatment with the angiotensin II receptor blocker (ARB) losartan for 12 months did not reduce the rate of brain atrophy, findings from the phase II RADAR* trial suggest.

In breast cancer patients treated with anthracycline-containing regimens, reducing the first-day dose of dexamethasone does not yield significant gastrointestinal benefit and is not recommended for nausea management, a recent study has found.

Sildenafil orally disintegrating strips (ODS) are just as effective and safe as the conventional tablet formulation for the treatment of erectile dysfunction (ED), a Thai study suggests.

A daily 100 mg dose of aspirin for 7 years did not reduce the risk of dementia in individuals with diabetes and no history of cardiovascular disease (CVD), according to results of the ASCEND* study presented at AHA 2021.

Treatment with the monoclonal antibody targeting interleukin [IL]-23p19 guselkumab 100 mg, given either every 4 (Q4W) or 8 weeks (Q8W), is well tolerated in patients with psoriatic arthritis (PsA), with no new safety concerns through 1 year, according to pooled results of the DISCOVER-1 and DISCOVER-2 phase III trials.